NYMX Pharmaceutical Corporation

Nasdaq: NYMX

"… working to introduce a new, safe, efficacious and long-lasting therapy to the millions of men suffering from an enlarged prostate gland (BPH)".



February 2022

FORWARD LOOKING STATEMENTS:

Certain information contained in this presentation may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Such forward-looking statements or information include, without limitation, statements or information about the results of our studies, anticipated financial performance, business prospects, strategies, regulatory developments and market acceptance. Forward-looking statements and information can be identified by the use of words such as “anticipated”, “expected”, “estimated” or similar words and phrases that state or indicate that certain actions, events or results “may”, “could”, “might” or “will” be taken, occur or be achieved.

Such statements or information reflect Nymox Pharmaceutical Corporation’s current views with respect to future events and are subject to certain risks, uncertainties and assumptions including, without limitation, the actual results of our studies, our actual financial performance, our ability to carry out our research and development plans, including our ability to obtain or maintain regulatory approvals, competition and market demand for any future product and our ability to obtain financing.

Forward-looking statements and information are necessarily based upon estimates and assumptions that, while considered reasonable by management, are inherently subject to significant risk and uncertainty. Many factors could cause our actual results, performance or achievements to be materially different from those that may be expressed or implied by such forward-looking statements or information. Such factors and corresponding risks and uncertainties are detailed in Nymox Pharmaceutical Corporation’s SEC filings. Should one or more of these risks or uncertainties materialize, or if assumptions underlying the forward-looking statements or information prove incorrect, actual results may vary materially from those described herein. Except as required by law, Nymox Pharmaceutical Corporation expressly disclaims any intention or obligation to update or revise any forward-looking statements and information. All forward-looking statements and information are expressly qualified in their entirety by the foregoing cautionary statements.

NYMOX MISSION

NYMOX IS DEVELOPING A NOVEL, PROPRIETARY TREATMENT FOR A CHRONIC CONDITION THAT NEGATIVELY IMPACTS THE LIVES OF MOST AGEING MEN ABOVE 60 AROUND THE WORLD:

BENIGN PROSTATIC HYPERPLASIA (BPH)*

* Worldwide incidence of >100M men today.

Symbol Nasdaq: **NYMX**

Main Assets


Fexapotide Triflutate
(NX-1207)
Benign Prostate Hyperplasia
BPH
Early Stage Prostate
Cancer
Status
Status
• Phase III Clinical Program in the U.S.: Completed
• Pre-NDA meeting with the FDA: Completed
• Regulatory filings with FDA & EMA: In preparation
• Manufacturing milestones: Achieved
> Successful large Phase II: Completed
> Registrational study: In preparation

THE NYMOX TREATMENT
for BPH

Drug Name: *Fexapotide Triflutate (FT)*

(formerly NX-1207)

Symbol Nasdaq: **NYMX**

Transrectal Injection Into the Prostate*



Enlarged Prostate



Two painless injections (few min office procedure)
> Transrectally, under ultrasound guidance.
> No anesthetics / no sedation required
> Drug injected into the «transition zone».

DRUG MECHANISM:
> Induces apoptosis (natural cell death).
> Cells die naturally and lessens pressure on the urethra

*** These are schematic illustrations for communication purposes and are not to be considered medically accurate.**

Status of Clinical Program in BPH:

- Two large Phase III Trials in the United States: COMPLETED
- More than 70 clinical sites across the U.S. involved.
- 977 men treated in the pivotal Phase III studies plus 344 additional treatments with re-injections = 1321 Phase 3 trial injection procedures.
- Up to six-year clinical follow-up on study-participants.

Nymox Comments:

- ✓ Phase 3 clinical trials completed and fully paid.
- ✓ Treatment effect is now well established and documented.
- ✓ Clinical trial results available on-line in prestigious peer review international urology publication. Link: https://www.ncbi.nlm.nih.gov/pubmed/29380128
- ✓ Extensive highly detailed fully disclosed data from clinical program in 2 recent peer review publications:
  - 2018: World Journal of Urology 2018; 36: 801-809
  - 2019: Therapeutic Advances Urology 2019; 11: 1-16

Demonstrated Long-term Clinical Benefits: [1,2]

- Long-lasting BPH Symptom Relief (>6 years), based on one treatment. Treatment can be safely repeated with additional therapeutic benefit.
- FT provides much greater symptom relief than seen with oral medications, without the side-effects seen with oral medications.
- Excellent Safety: No drug related adverse side-effects. Improved sexual function.
- Statistically significant reduction in the incidence of prostate cancer over the long-term.
- Statistically significant reduced need for surgical intervention long-term.
- All alternative treatment options (oral medication, minimally invasive procedures and surgery) are associated with clinically meaningful adverse side-effect profiles.

[1)] World J Urol 2018; 36: 801-809
[2)] Ther Adv Urol 2019; 11: 1-16

Efficacy Results Summary From U.S. Phase III Studies [1,2]

Change From Baseline = Benefit to Patient

- **5.7 points improvement** at 3.6 years after single injection
- **6.6 points improvement** in first-line patients (**treatment naïve**) at 3.6 years after single injection.
- **> 8 points** improvement after 2 injections.

Comment:

Patients have substantial symptom improvement as soon as 10 days after treatment. Long-term a second injection confers on average over 8 points IPSS improvement from baseline.

References:
[1)] World J Urol 2018; 36: 801-809
[2)] Ther Adv Urol 2019; 11: 1-16

Fexapotide Triflutate Data Has Been Highly and Repeatedly Scrutinized

- Nymox Phase III clinical trial results have been presented multiple times by leading U.S. urologists at regional and national AUA meetings* in 2017 and 2018.

* Northeast AUA Annual Meeting, Savannah, GA, October 12, 2017; New York AUA Annual Meeting, Havana, Cuba, November 6, 2017; North Central AUA Annual Meeting, Scottsdale AZ, November 15, 2017; South Central AUA Annual Meeting, Naples FL, November 27, 2017; Mid-Atlantic AUA Annual Meeting, Amelia Island FL, March 3, 2018; AUA Annual Meeting San Francisco CA, May 20, 2018.

Fexapotide Triflutate Data Has Been Highly and Repeatedly Scrutinized

- Study results published and discussed in:
  - **World Journal of Urology** (January 2018). Indication: BPH
  - **Therapeutic Advances in Urology** (January 2019). Indication BPH.
  - **Research and Reports in Urology** (December 2019): FT Mechanism of Action
  - **World Journal of Urology** (February 2020): Indication: Early-Stage Prostate Cancer

World Journal of Urology
https://doi.org/10.1007/s00345-018-2185-y

ORIGINAL ARTICLE

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement

Neal Shore[1] · Ronald Tutrone[2] · Mitchell Efros[3] · Mohamed Bidair[4] · Barton Wachs[5] · Susan Kalota[6] · Sheldon Freedman[7] · James Bailen[8] · Richard Levin[9] · Stephen Richardson[10] · Jed Kaminetsky[11] · Jeffrey Snyder[12] · Barry Shepard[13] · Kenneth Goldberg[14] · Alan Hay[15] · Steven Gange[16] · Ivan Grunberger[17]

Multiple Long-term Treatment Benefits of FT:

- **Cancer Benefit** (June 2016): Company reported significantly lower long-term incidence (lower risk) of prostate cancer in men treated for their BPH with FT in the Phase III FT Study program for BPH. FT Cancer Incidence: 1.3%, Placebo: 6.3%.
- **Less Need for Surgery** (August 2016): For patients in the Phase III BPH trials who initially received placebo and subsequently crossed over to either FT or conventional therapies, there was an >80% reduction in the eventual need for surgery in the FT treated group.
- **Repeat FT Tre**atment (October 2016) is safe and induces long-term BPH symptom relief up to 6 years after initial treatment. *No other prior prostate injectable candidate treatment has ever been shown to be adequately safe for repeat injections -- and no other candidate treatment has been shown to produce statistically significant long-term improvement in patients with BPH.*
- Superior results (symptom relief) both short- and long-term as a first-line treatment (November 2016).
- **Improved sexual function** in FT treated group (May 2017)

Fexapotide Therapy Summary / Profile:

Considerably more efficacious and longer lasting than currently used oral therapies.

Minimal side-effects – currently prescribed therapies have significant side-effect profiles.

Durable treatment effect. Easy for patients to comply with therapy.

Cancer inhibitory properties.

Quick, painless procedure in the doctor's office.

Improved sexual function, no incontinence and no effect on testosterone levels. Maintained quality of life.

Corporate Summary

- Block-buster market opportunity; >100M potential patients WW.
- No competition.
- Potentially Disease Modifying Treatment:
  - Demonstrated *greater efficacy* than current non-surgical treatment modalities
  - Demonstrated *reduced incidence of surgery* in treated patients.
  - Demonstrated *reduced incidence of urinary retention* in treated patients.
  - Demonstrated *reduced long-term incidence of prostate cancer* in treated patients.
  - *Minimal side-effects.* Treatment is extremely safe.
  - *Improved sexual function;* no treatment induced damage to nerves.
  - Treatment can be *safely repeated*.
- Company owns 100% commercial rights worldwide.
- Strong IP: Several new, recently issued patents.

Corporate Summary

- NDA (New Drug Application) to be filed in the U.S. with the FDA for Nymox' lead product candidate (Fexapotide Triflutate) in BPH.
- European filing will follow the NDA filing in the U.S.
- Shares outstanding: approx. 85M.
- Clean capital structure, no debt.
- No major lingering expenses. All reported trials have been paid for.

Upcoming Corporate Milestones

- Filings for Regulatory Approvals in the United States and Europe.
- Clinical advancement of Fexapotide Triflutate for early-stage prostate cancer.
- Augmented and enhanced management team members.
- Preparations for commercialization.
- Potential Commercial Partnerships.
- Additional Clinical Publications.
- Obtain regulatory clearance for FT in BPH.

Pharmaceutical Corporation

Nasdaq: NYMX

For further information, please contact:

Erik Danielsen
CFO
Info@Nymox.com